Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06445062 · ClinicalTrials.gov registry record · Phase 1
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
A Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Revolution Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 1,130
- Enrollment target
- 20
- Study locations
NCT06445062 is a Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 1,130 participants, below the 1,508-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06445062, a Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Revolution Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 1,130 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel
Conditions Studied
Interventions
- DRUG cetuximab
- DRUG RMC-6236
- DRUG bevacizumab
- DRUG mFOLFOX6 regimen
- DRUG mFOLFIRINOX regimen
Study Locations (20)
Arizona
- Ironwood Cancer and Research Centers - Chandler
- Mayo Clinic Hospital - Phoenix
- HonorHealth Research Institute - Scottsdale
California
- UC San Diego Moores Cancer Center - La Jolla
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center - Los Angeles
- UCLA Hematology/Oncology- Santa Monica - Los Angeles
Florida
- Mayo Clinic Cancer Center - Jacksonville
- Moffitt Cancer Center - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Nebraska
- Nebraska Cancer Specialists - Omaha
- University of Nebraska Medical Center - Omaha
New York
- Northwell Health / RJ Zuckerberg Cancer Center - Lake Success
- Columbia University Medical Center - New York
Colorado
- University of Colorado Hospital-Anschutz Cancer Pavilion - Aurora
Connecticut
- Yale-New Haven Hospital-Yale Cancer Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,130 participants |
| Start Date | 2024-05-24 |
| Est. Completion | 2027-07-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06445062
The ClinicalTrials.gov registry entry for NCT06445062 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 1,130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,508-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (25% lower). The listed sponsor is Revolution Medicines, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which cetuximab is the first listed.
NCT06445062 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06445062 about?
NCT06445062 is a clinical study titled "Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors". The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + ...
What is the current status of trial NCT06445062?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 1,130 participants. The study started on 2024-05-24. Estimated completion is 2027-07-15.
What conditions does trial NCT06445062 study?
This clinical trial studies the following conditions: Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, CRC.
What interventions are being tested in trial NCT06445062?
The interventions under investigation include: cetuximab (DRUG), RMC-6236 (DRUG), bevacizumab (DRUG), mFOLFOX6 regimen (DRUG), mFOLFIRINOX regimen (DRUG).
Who is sponsoring clinical trial NCT06445062?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06445062 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.